Neogenomics (NEO) Total Current Liabilities (2010 - 2026)

Neogenomics (NEO) has 17 years of Total Current Liabilities data on file, last reported at $105.9 million in Q2 2026.

• Quarterly Total Current Liabilities rose 5.76% year-over-year to $105.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $105.9 million (up 5.76% YoY) and the FY2025 annual result came in at $88.3 million, down 70.69% from the prior year.
• Total Current Liabilities advanced to $105.9 million in Q2 2026, from $84.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $301.2 million in Q4 2024 to a low of $76.7 million in Q1 2024.
• A 5-year average of $135.1 million and a median of $93.9 million in 2023 frame the typical range for Total Current Liabilities.
• The widest YoY moves for Total Current Liabilities: up 264.61% in 2025, down 70.69% in 2025.
• Tracing NEO's Total Current Liabilities over 5 years: stood at $89.9 million in 2022, then increased by 7.09% to $96.3 million in 2023, then jumped by 212.8% to $301.2 million in 2024, then plunged by 70.69% to $88.3 million in 2025, then increased by 19.91% to $105.9 million in 2026.
• The last three Total Current Liabilities figures came in at $105.9 million (Q2 2026), $84.6 million (Q1 2026), and $88.3 million (Q4 2025), per Business Quant data.